1. Diabetes and Cardiovascular Disease Risk: The Hard Truth

2. Learning Objectives

5. DIGAMI 1: Mortality after AMI

8. Glucose Therapy Intensification (GTI) Among Patients with Diabetes

9. Intensive Treatment of T2DM: Macrovascular Complications

11. Impact of Intensive Therapy in T2DM

12. Meta-Analysis of Intensive vs Standard Care*

13. Recommendations for Treatment of T2DM

15. VA-HIT: Gemfibrozil Prevents Secondary CVD Events

19. SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2DM

20. AleCardio: Aleglitazar in Patients With T2D and ACS*

21. Managing CV Risk in Patients with T2DM: Concluding Remarks